Investing.com - UroGen Pharma (NASDAQ: URGN) reported first quarter EPS of $-0.72, $0.04 worse than the analyst estimate of $-0.68. Revenue for the quarter came in at $23.53M versus the consensus estimate of $22.56M.
Guidance
UroGen Pharma sees FY 2024 revenue of $95.00M-$102.00M versus the analyst consensus of $108.70M.
UroGen Pharma's stock price closed at $17.47. It is up 16.47% in the last 3 months and up 81.41% in the last 12 months.
UroGen Pharma saw 1 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See UroGen Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, UroGen Pharma's Financial Health score is "good performance".
Check out UroGen Pharma's recent earnings performance, and UroGen Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar